Ando Koji, Oki Eiji, Kakeji Yoshihiro, Sugiyama Masahiko, Saeki Hiroshi, Endo Kazuya, Morita Masaru, Emi Yasunori, Maehara Yoshihiko
Dept. of Surgery and Science, Graduate School of Medical Sciences, Kyushu University.
Gan To Kagaku Ryoho. 2008 Nov;35(12):2192-4.
Recently, standard therapies for either gastric cancer or colorectal cancer have been established through the development of multidrug systemic chemotherapy and the appearance of molecular targeting drugs. For example, either FOLFIRI or FOLFOX therapy is normally chosen for the treatment of unresectable liver metastasis from colorectal cancer. On the other hand, hepatic artery infusion (HAI) chemotherapy is generally used as only a second-line therapy. There are, however, some cases in which systemic chemotherapy is not indicated due to age and/or the risk of side effects. We herein report three cases that were treated by HAI after initially performing systemic chemotherapy in order to treat liver metastasis from either gastric cancer or colorectal cancer.
近年来，通过多药全身化疗的发展和分子靶向药物的出现，胃癌或结直肠癌的标准治疗方法已经确立。例如，FOLFIRI或FOLFOX疗法通常被选择用于治疗不可切除的结直肠癌肝转移。另一方面，肝动脉灌注（HAI）化疗通常仅用作二线治疗。然而，在某些情况下，由于年龄和/或副作用风险，全身化疗并不适用。我们在此报告三例在最初进行全身化疗以治疗胃癌或结直肠癌肝转移后接受HAI治疗的病例。
